Phase 1 dose-finding study of topical neostigmine ophthalmic solution for alleviating myasthenic ptosis
Chuthamas Ongprakobkul, Supanut Apinyawasisuk, Supharat Jariyakosol, Pajaree Chariyavilaskul, Kornvalee Meesilpavikkai, Yuda Chongpison · 2026
Read Phase 1 dose-finding study of topical neostigmine ophthalmic solution for alleviating myasthenic ptosis by Chuthamas Ongprakobkul, Supanut Apinyawasisuk, Supharat Jariyakosol, Pajaree Chariyavilaskul, Kornvalee Meesilpavikkai, Yuda Chongpison (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13324272.txt.
Description
Six authors, led by Chuthamas Ongprakobkul, report a 2026 Phase 1 study of an eye drop for people with myasthenia gravis. The condition weakens muscles, and one common sign is ptosis, a drooping upper eyelid. The drop holds a drug called neostigmine, placed right on the eye.
The team ran a dose-finding study with small groups of three patients at each step. The first group got the lowest dose, and later groups got the dose picked from earlier results. The team tracked safety through vital signs, vision, eye pressure, pupil size, and eye exams. They measured benefit through the height of the eyelid opening and what patients reported. No side effects in the body or the eye were seen in any patient.
Catalog record
| CREATOR | Chuthamas Ongprakobkul, Supanut Apinyawasisuk, Supharat Jariyakosol, Pajaree Chariyavilaskul, Kornvalee Meesilpavikkai, Yuda Chongpison |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |